• University of Michigan Medical Center renews 3-year contract valued at AUD$155,000
• Contract allows access to 4DMedical's full suite of structural lung analysis products
• New multicentre study demonstrates power of 4DMedical's functional biomarkers
• 4DMedical awarded AUD$3.8m grant to advance AI lung function analysis

4DMedical Limited (ASX:4DX), a global leader in respiratory imaging technology, is pleased to announce the renewal of its contract with the University of Michigan Medical Center, one of the leading academic medical centres in the United States, for a further three-year term. Under the renewed contract, which runs from 1 July 2025 to 30 June 2028, 4DMedical will provide University of Michigan clinicians and researchers with access to its full suite of structural lung analysis applications via the Enterprise Core Computing Platform (CCP). This includes CT Lung Density Analysis - Inspiration (LDAi), CT Lung Density Analysis - Functional (LDAf), Pulmonary Hypertension Analysis (PHA), and investigational use of Lung Texture Analysis (LTA), subject to FDA clearance. The contract has a total value of approximately AUD$155,000 over three years. In addition to the contract renewal, 4DMedical welcomes the recent publication of a major new multicentre study in Respiratory Research (July 2025), which demonstrated that 4DMedical's X-ray Velocimetry Lung Ventilation Analysis Software (XV LVAS®) can detect early and subtle forms of small airways disease that are often missed by standard tests like spirometry and CT scans. The study showed that XV LVAS® offered actionable insights for optimised patient care and could reduce the need for invasive lung biopsy. 4DMedical has also been awarded AUD$1.1 million in non-dilutive cash funding under Round 1 of Australia's Economic Accelerator (AEA) Innovate grant program. The project will develop novel AI-derived functional biomarkers to enhance respiratory disease diagnosis and treatment.

The biomarkers derived from XV LVAS® findings are game-changing for the field of pulmonary imaging. We are entering a new era where 'the gold standard' for lung disease evaluation will include quantitative, reproducible metrics such as the DR-CB biomarker alongside traditional radiological reads. This body of work exemplifies how functional imaging can not only enhance clinical decision-making, but also elevate the standard of care for patients around the world.